BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 30386679)

  • 1. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.
    Thomas A; Routh ED; Pullikuth A; Jin G; Su J; Chou JW; Hoadley KA; Print C; Knowlton N; Black MA; Demaria S; Wang E; Bedognetti D; Jones WD; Mehta GA; Gatza ML; Perou CM; Page DB; Triozzi P; Miller LD
    Oncoimmunology; 2018; 7(10):e1490854. PubMed ID: 30386679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer.
    Katsuta E; Yan L; Opyrchal M; Kalinski P; Takabe K
    Ther Adv Med Oncol; 2021; 13():17588359211006680. PubMed ID: 33868461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
    Wang J; Zhang X; Li J; Ma X; Feng F; Liu L; Wu J; Sun C
    Aging (Albany NY); 2020 Nov; 13(1):351-363. PubMed ID: 33234738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers.
    Wu HX; Wang ZX; Zhao Q; Chen DL; He MM; Yang LP; Wang YN; Jin Y; Ren C; Luo HY; Wang ZQ; Wang F
    Ann Transl Med; 2019 Nov; 7(22):640. PubMed ID: 31930041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer.
    Zhao DY; Sun XZ; Yao SK
    World J Gastrointest Oncol; 2021 Jan; 13(1):37-57. PubMed ID: 33510848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between tumor mutation burden and immune infiltration in ovarian cancer.
    Mi JL; Xu M; Liu C; Wang RS
    Int J Clin Exp Pathol; 2020; 13(10):2513-2523. PubMed ID: 33165430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiomics analysis of tumor mutational burden across cancer types.
    Li L; Bai L; Lin H; Dong L; Zhang R; Cheng X; Liu Z; Ouyang Y; Ding K
    Comput Struct Biotechnol J; 2021; 19():5637-5646. PubMed ID: 34745455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis.
    Yan J; Wu X; Yu J; Zhu Y; Cang S
    Front Oncol; 2020; 10():570654. PubMed ID: 33240814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer.
    Xiao W; Zhang G; Chen B; Chen X; Wen L; Lai J; Li X; Li M; Liu H; Liu J; Han-Zhang H; Lizaso A; Liao N
    Front Oncol; 2021; 11():618767. PubMed ID: 33968723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes.
    Teng X; Yang T; Yuan B; Yang Y; Liu J; Wang X; Wang Y; Ma T; Yin X; Yu H; Wang S; Huang W
    Front Oncol; 2023; 13():1177133. PubMed ID: 37350936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Analysis of Copy Number Variation, Microsatellite Instability, and Tumor Mutation Burden Identifies an 11-Gene Signature Predicting Survival in Breast Cancer.
    Jin X; Yan J; Chen C; Chen Y; Huang WK
    Front Cell Dev Biol; 2021; 9():721505. PubMed ID: 34650974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database.
    Xu M; Li Y; Li W; Zhao Q; Zhang Q; Le K; Huang Z; Yi P
    Front Med (Lausanne); 2020; 7():64. PubMed ID: 32195260
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
    Jang BS; Han W; Kim IA
    Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel.
    Zhuang W; Ma J; Chen X; Wang G; Lu J; Chen Y; Dong H; Cai S; Zhang Y; Zhao X; Zhu Y; Xu C; Huang Y; Huang Z; Zhu X; Jiang H; Wang Z
    J Cancer; 2018; 9(13):2302-2307. PubMed ID: 30026825
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
    Patel RR; Ramkissoon SH; Ross J; Weintraub L
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.